Diasome Pharmaceuticals has released Phase 2b clinical data showing its HDV-insulin lispro formulation maintained glycemic control while reducing the incidence of hypoglycemia in adults with Type 1 diabetes. The findings, which draw on the company's proprietary hepatocyte-directed vesicle (HDV) delivery platform, underscore a growing body of research into targeted nutrient and hormone delivery that is being watched closely by the functional-foods and nutraceutical sector.
The HDV platform works by encapsulating insulin lispro in phospholipid-based vesicles engineered to preferentially target hepatic tissue — the liver's central role in glucose homeostasis being the key mechanistic rationale. By directing insulin activity toward the liver first, the technology aims to more closely replicate physiological insulin secretion patterns, reducing peripheral hyperinsulinemia and the downstream hypoglycemic risk that standard mealtime insulin carries. While the compound itself is a regulated pharmaceutical, the lipid-vesicle delivery architecture shares conceptual and materials overlap with liposomal delivery systems increasingly deployed in finished supplement formulations targeting metabolic health.
For operators in the functional-food space, the clinical endpoint data from a double-blind, placebo-controlled Phase 2b study carries translational weight. Bioavailability engineering — whether applied to a pharmaceutical insulin analog or a botanical standardized extract — faces the same fundamental challenge: getting the active compound to the right tissue at the right concentration. The HDV results add peer-reviewed weight to the argument that lipid-based carrier systems can meaningfully shift pharmacokinetic profiles, a conversation active in nutraceutical co-manufacturing and white-label delivery-system development.
The metabolic health category remains one of the highest-growth segments across the functional-foods and dietary supplement landscape, driven by consumer demand for blood sugar management solutions, insulin sensitivity support, and weight-related structure-function claims. Ingredients such as berberine, chromium picolinate, and alpha-lipoic acid compete for formulation shelf space alongside emerging phospholipid-complex and liposomal delivery formats. Diasome's Phase 2b data, while pharmaceutical in origin, will likely accelerate ingredient supplier investment in hepatocyte-targeting delivery science applicable to GRAS-affirmed and NDI-notified compounds.
Industry observers note that as the line between advanced drug-delivery science and nutraceutical bioavailability engineering continues to blur, finished-formulation brands willing to invest in clinically validated delivery platforms stand to differentiate in an increasingly crowded metabolic-health market. The Diasome data set provides a useful clinical-trial benchmark for the kind of endpoint rigor — reduction in adverse events alongside maintained efficacy — that premium nutraceutical positioning increasingly requires.
Written by Michael Politz, Author of Guide to Restaurant Success: The Proven Process for Starting Any Restaurant Business From Scratch to Success (ISBN: 978-1-119-66896-1), Founder of Food & Beverage Magazine, the leading online magazine and resource in the industry. Designer of the Bluetooth logo and recognized in Entrepreneur Magazine's "Top 40 Under 40" for founding American Wholesale Floral, Politz is also the Co-founder of the Proof Awards and the CPG Awards and a partner in numerous consumer brands across the food and beverage sector.